ClinicalTrials.gg
RecruitingNCT06720987Updated Nov 3, 2026

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Phase 1 interventional study of KQB365 and Cetuximab in KRAS G12C Mutation, KRAS G12S Mutation and Solid Tumor Malignancies, sponsored by Kumquat Biosciences Inc.. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Kumquat Biosciences Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 3, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,341 studies in Colorectal Neoplasms with a site in United States — 417 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
650th of 1,933
140 · median 64
Started
2025
with 143 others
Phase 1
551 of 2,341
100 open now
Primary completion
2029-06
later than 539 of 627 live
Registered
2,100th of 2,341
by date

Among the 2,341 studies in Colorectal Neoplasms with a site in United States, this one is the 650th largest by planned enrollment of the 1,933 interventional ones that give a count, is one of 144 that started in 2025, is one of 551 in phase 1, reaches primary completion later than 539 of the 627 other live ones, and was the 2,100th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

417 of the 2,341 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 417 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,341 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are:

  • What is the safe dose of KQB365 by itself, in combination with cetuximab, or in combination with KQB198?
  • Does KQB365 alone, in combination with cetuximab, or in combination with KQB198 decrease the size of the tumor?
  • What happens to KQB365 in the body?

Participants will:

  • Receive KQB365 infusion weekly alone, in combination with cetuximab, or in combination with oral KQB198.
  • Visit the clinic about 9 times in the first 6 weeks, and then once every week after that.
03

Conditions studied

  • KRAS G12C Mutation
  • KRAS G12S Mutation
  • Solid Tumor Malignancies
  • CRC (Colorectal Cancer)
  • NSCLC
  • NSCLC (Non-small-cell Lung Cancer)
  • NSCLC Non-small Cell Lung Cancer
  • Lung Cancer (Non-Small Cell)
  • KRAS G12-mutant NSCLC

Keywords

  • cetuximab
  • KQB365
  • KQB198
  • kras
  • inhibitor
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PART 1 (monotherapy and combo therapy with KQB198): confirmed diagnosis of a solid tumor with either a KRAS G12C or KRAS G12S mutation.
  • PART 1 (combo therapy with Cetuximab) \& PART 2: Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with either a KRAS G12C or KRAS G12S mutation.
  • PART 1 (monotherapy Non-Small Cell Lung Cancer Cohort): Histologically confirmed diagnosis of Non-Small Cell Lung Cancer with either a KRAS G12C or KRAS G12S mutation.
  • Unresectable or disease
  • No available treatment with curative intent
  • Adequate organ function
  • per v1.1

Exclusion criteria

Exclusion Criteria:

  • Active primary central nervous system tumors
  • Cardiac abnormalities
  • Active interstitial lung disease
  • Unable to swallow or GI condition that prevents absorption for patients in KQB198 combination cohorts
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation (Part 1)

    Drug: KQB365 \- Intravenous KQB365

    Drug: KQB365

  • Experimental
    Combo Therapy with Cetuximab Dose Escalation (Part 1)

    Drug: KQB365 - Intravenous KQB365 Drug: \- Intravenous cetuximab

    Drug: KQB365 · Drug: Cetuximab

  • Experimental
    Monotherapy Dose Expansion - RP2D (Part 2)

    Drug: KQB365 \- Intravenous KQB365

    Drug: KQB365

  • Experimental
    Monotherapy Dose Expansion - RP2D-1 (Part 2)

    Drug: KQB365 \- Intravenous KQB365

    Drug: KQB365

  • Experimental
    Combo Therapy with Cetuximab Dose Expansion - RP2D (Part 2)

    Drug: KQB365 - Intravenous KQB365 Drug: \- Intravenous cetuximab

    Drug: KQB365 · Drug: Cetuximab

  • Experimental
    Combo Therapy with Cetuximab Dose Expansion - RP2D-1 (Part 2)

    Drug: KQB365 - Intravenous KQB365 Drug: \- Intravenous cetuximab

    Drug: KQB365 · Drug: Cetuximab

  • Experimental
    Combo Therapy with KQB198 Dose Escalation (Part 1)

    Drug: KQB365 - Intravenous KQB365 Drug: \- Oral KQB198

    Drug: KQB365 · Drug: KQB198

Interventions

  • DrugKQB365

    Intravenous KQB365

  • Intravenous cetuximab

  • DrugKQB198

    Oral KQB198

06

What researchers measure

Primary outcomes

  1. Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)

    Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 30 days after last dose of study treatment.

    Time frame: From enrollment to the end of treatment

  2. Recommended Phase 2 Dose (RP2D) (Part 1)

    Evaluate safety and assess number of patients with dose-limiting toxicity to determine the RP2D.

    Time frame: up to 35 months

  3. Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR) (Part 2)

    ORR is the proportion of subjects that experience confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 during the time period from 1st dose of study treatment until last dose.

    Time frame: up to 35 months

Secondary outcomes

  1. Concentration-time curve (AUC)

    Time frame: up to 35 months

  2. Maximum plasma concentration (Cmax)

    Time frame: up to 35 months

  3. Time to maximum plasma concentration (tmax)

    Time frame: up to 35 months

  4. Overall survival (OS)

    Time frame: up to 35 months

  5. Progression-free survival (PFS)

    using RECIST v1.1

    Time frame: up to 35 months

  6. Overall response rate (ORR)

    using RECIST v1.1

    Time frame: up to 35 months

  7. Duration of response (DOR)

    using RECIST v1.1

    Time frame: up to 35 months

  8. Time to response (TTR)

    using RECIST v1.1

    Time frame: up to 35 months

  9. Disease control rate (DCR)

    using RECIST v1.1

    Time frame: up to 35 months

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2029, 52 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 52 months is above that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Dec 6, 2024
StartActual
Feb 4, 2025
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedPART 1 (monotherapy Non-Small Cell Lung Cancer Cohort): Histologically confirmed diagnosis of Non-Small Cell Lung Cancer with either a KRAS G12C or KRAS G12S mutation.
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedPART 1 (monotherapy Non-Small Cell Lung Cancer Cohort): Histologically confirmed diagnosis of Non-Small Cell Lung Cancer with either a KRAS G12C or KRAS G12S mutation.
    + 4 other changes: index terms, verification date, conditions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06720987
Lead sponsor
Kumquat Biosciences Inc.
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Feb 4, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Kumquat Clinical Development
Contact
kumquatstudies@kumquatbio.com
(858) 214-2700

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion